These findings cast doubts on the therapeutic usefulness of SIRT1 activators as candidates to control alterations in early AD, while prompting the quest for other systems controlling PFC-LTP that might be of interest to develop strategies to manage the onset of AD. This evidence concerns the gene SIRT1 and Alzheimer disease.